We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · May 19, 2022

Final Analysis of 3 vs 6 Months of Adjuvant FOLFOX or CAPOX for Stage III Colon Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial
J. Clin. Oncol 2022 May 05;[EPub Ahead of Print], T Yoshino, E Oki, T Misumi, M Kotaka, D Manaka, T Eto, J Hasegawa, A Takagane, M Nakamura, T Kato, Y Munemoto, F Nakamura, H Bando, H Taniguchi, Y Sakamoto, M Shiozawa, M Nishi, T Horiuchi, H Yamagishi, J Sakamoto, T Mizushima, A Ohtsu, M Mori

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading